A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Zenocutuzumab is a first-in-class bispecific antibody that inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 fusions.
This Viewpoint discusses cancer antigen expression and antibody drug conjugates.
An abstract is unavailable.
First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients…
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.
Abstract. BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymp
After receiving a metastatic colorectal cancer diagnosis, Jeff Williams was told he didn’t qualify for surgery. After coming to MD Anderson for a second opinion,…
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products